Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Overall survival lower with cetuximab in oropharyngeal cancer

Mehanna H et al. ESMO 2018, Abstract LBA9_PR

Key clinical point: Radiation and concomitant cisplatin remains the standard of care for patients with low-risk human papillomavirus–positive oropharyngeal cancer.

Major finding: The 2-year overall survival was 97.5% with cisplatin versus 89.4% with cetuximab (P = .001).

Study details: A randomized trial in 334 patients with low-risk oropharyngeal cancer.

Disclosures: The study was sponsored by the University of Warwick (England), University of Birmingham, University of Oxford (England), and Cancer Research UK. Dr. Mehanna reported honoraria from AstraZeneca, MSD, Sanofi Pasteur, and Merck, and is a director and stockholder of the Warwickshire Head and Neck Clinic. Dr. Psyrri reported honoraria from Merck Serono, Roche, MSD, AstraZeneca, Bristol-Myers Squibb, Bayer, Pfizer, Medscape, and Prime Oncology. Dr. Machiels reported a consulting or advisory role with Boehringer Ingelheim, Debiopharm Group, Innate Pharma, Merck, Nanobiotix, and Pfizer, and research funding from Bayer, Janssen Pharmaceuticals, Novartis, and Sanofi.

Read the article here.


Mehanna H et al. ESMO 2018, Abstract LBA9_PR.

This Week's Must Reads

PFS superior with avelumab and axitinib in advanced RCC, Motzer RJ et al. ESMO 2018. Abstract LBA6_PR

Adjuvant axitinib may benefit highest risk RCC patients, Quinn DI et al. Ann Oncol. 2018 Oct 20. doi: 10.1093/annonc/mdy454

High KPNA2 signals poor outcomes for RCC, Kristiansen G et al. Clin Genitourin Cancer. 2018 Oct 22. doi: 10.1016/j.clgc.2018.10.008

RCC patient and disease characteristics differ by race/ethnicity, Batai K et al. Clin Genitourin Cancer. 2018 Oct 26. doi: 10.1016/j.clgc.2018.10.012

Change in tumor burden signals treatment needs in mRCC, Bimbatti D et al. Urol Oncol. 2018 Oct 6. doi: 10.1016/j.urolonc.2018.08.018

Must Reads in Head & Neck Cancers

Overall survival lower with cetuximab in oropharyngeal cancer, Mehanna H et al. ESMO 2018, Abstract LBA9_PR

Head and neck cancer therapy toxicities greater in women, Cristina V et al. JAMA Oncol. 2018 May 24. doi: 10.1001/jamaoncol.2018.1080.

CYCORE reduces radiotherapy side effects in head and neck cancers, Peterson et al. ASCO 2018, Abstract 6063

Metastatic Lymph Nodes and Oral Cancer Survival , J Clin Oncol; ePub 2017 Sep 7; Ho, Kim, et al

Surgery Plus Chemoradiotherapy for Esophageal Ca, Cochrane; 2017 Aug 22; Vellayappan, et al